trending Market Intelligence /marketintelligence/en/news-insights/trending/_reynvpfmnqdkviglct0gg2 content esgSubNav
In This List

Japan court rules in favor of Roche in Hemlibra patent case vs. Shire

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Japan court rules in favor of Roche in Hemlibra patent case vs. Shire

Roche Holding AG said a Japanese court ruled in favor of Chugai Pharmaceutical Co. Ltd. in a patent infringement case relating to hemophilia A drug Hemlibra versus Irish biotech Shire Plc.

The Tokyo District Court dismissed Shire's claims that Hemlibra, also known as emicizumab or ACE910, infringes patents held by Shire units Baxalta Inc. and Baxalta GmbH.

Shire was also seeking a preliminary injunction in the U.S. against Roche units Chugai and Genentech to limit sales of Hemlibra, which obtained U.S. Food and Drug Administration approval in November 2017.

Hemlibra has also received approvals from the European Medicines Agency and most recently Japan's Ministry of Health, Labour and Welfare.

SNL Image